In a hospital pharmacy in the north of England, the working day often starts with a list of what has not arrived. A generic antibiotic is short. An epilepsy treatment is on allocation, and someone must find a substitute before the ward round begins. The tablets in question were very probably made in Telangana or Gujarat, for a market where the price paid per box is among the lowest in any wealthy country. Few pharmacists think of this as trade policy. It is, and since 15 July it has had a treaty attached.

The India-UK Comprehensive Economic and Trade Agreement has now completed its first full month in operation. Bilateral trade in August rose by about 15 per cent to nearly $2 billion, with pharmaceuticals among the categories lifting Indian exports. The numbers are modest and one month proves little. A surge in silver shipments explains much of the rise in Indian purchases from Britain, which grew more than twice as fast as sales in the other direction. The pharmaceutical line still deserves the attention of NHS leaders, because it describes a dependency that already exists.

India supplies a large share of the generic medicines dispensed in the UK, and the economics are unforgiving. Generic prices are set by competition and by reimbursement arrangements that leave thin margins. When a manufacturer drops a product line or a single plant fails an inspection, there is little spare capacity and no financial cushion to draw in alternative supply. Shortages of common medicines have become a recurring operational burden, absorbing pharmacist time and sometimes pushing clinicians towards second-choice treatments. Removing tariffs trims some costs at the border. By itself it does nothing to change the pricing model that makes British supply fragile.

The second dependency is human. Doctors trained in India form one of the largest overseas groups on the UK medical register, and the NHS has relied on international recruitment to keep rotas filled in hospital medicine and psychiatry. The agreement includes arrangements on the movement of professionals and on social security contributions for temporary workers. Domestic politics, meanwhile, has moved towards lower net migration, tighter visa rules for care workers and louder scepticism about overseas recruitment. The Home Office and the Department for Business and Trade are pursuing aims that sit awkwardly together, and the Department of Health and Social Care is seldom the party that reconciles them.

For NHS leaders, the practical step is to treat supplier concentration as a mapped risk. Procurement teams and integrated care boards hold more data on single-source dependencies than ministers tend to use, and that data should inform national conversations about which medicines justify a security premium. Policymakers could pair tariff gains with price mechanisms that reward reliable supply, such as longer contracts and a willingness to pay modestly more for resilience in the handful of drugs that matter most clinically. Life sciences firms with Indian manufacturing partners will want clarity from the MHRA on how far it relies on inspections and approvals carried out elsewhere, since that determines how quickly new supply can be brought online when a gap opens.

There is a political dimension that ministers would prefer to leave unexamined. A government under pressure over waiting lists wants visible gains from trade and visible reductions in migration at the same moment. Both claims can be made in a speech. They are harder to sustain in a hospital where the rota depends on staff recruited abroad and the pharmacy depends on tablets made in Hyderabad.

The 15 per cent figure will fade from the headlines. The dependencies beneath it will remain. A trade agreement widens a channel, and what flows through it depends on pricing and migration policy, both of which sit with departments that were not the main authors of the deal. Ministers who want the agreement to deliver for patients should start with the pharmacist holding the spreadsheet.

‍